Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.
Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, Santra S, Smolen JS. Kavanaugh A, et al. Among authors: kupper h. Ann Rheum Dis. 2013 Jan;72(1):64-71. doi: 10.1136/annrheumdis-2011-201247. Epub 2012 May 5. Ann Rheum Dis. 2013. PMID: 22562973 Free PMC article. Clinical Trial.
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.
van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, Schattenkirchner M, Emery P, Burmester GR, Zeidler H, Moutsopoulos HM, Beck K, Kupper H. van de Putte LB, et al. Among authors: kupper h. Ann Rheum Dis. 2003 Dec;62(12):1168-77. doi: 10.1136/ard.2003.009563. Ann Rheum Dis. 2003. PMID: 14644854 Free PMC article. Clinical Trial.
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H. van de Putte LB, et al. Among authors: kupper h. Ann Rheum Dis. 2004 May;63(5):508-16. doi: 10.1136/ard.2003.013052. Ann Rheum Dis. 2004. PMID: 15082480 Free PMC article. Clinical Trial.
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
Burmester GR, Mariette X, Montecucco C, Monteagudo-Sáez I, Malaise M, Tzioufas AG, Bijlsma JW, Unnebrink K, Kary S, Kupper H. Burmester GR, et al. Among authors: kupper h. Ann Rheum Dis. 2007 Jun;66(6):732-9. doi: 10.1136/ard.2006.066761. Epub 2007 Feb 28. Ann Rheum Dis. 2007. PMID: 17329305 Free PMC article. Clinical Trial.
Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
van der Heijde D, Pangan AL, Schiff MH, Braun J, Borofsky M, Torre J, Davis JC Jr, Wong RL, Kupper H, Collantes E; ATLAS Study Group. van der Heijde D, et al. Among authors: kupper h. Ann Rheum Dis. 2008 Sep;67(9):1218-21. doi: 10.1136/ard.2007.082529. Epub 2007 Dec 4. Ann Rheum Dis. 2008. PMID: 18056755 Free PMC article. Clinical Trial.
266 results